Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-01

AUTHORS

I. Kümler, P. Grundtvig Sørensen, J. Palshof, E. Høgdall, W. Skovrider-Ruminski, S. Theile, A. Fullerton, P. G. Nielsen, B. Vittrup Jensen, D. L. Nielsen

ABSTRACT

BACKGROUND: Oral drug formulations have several advantages compared to intravenous formulation. Apart from patient convenience and favorable pharmacoeconomics, they offer the possibility of frequent drug administration at home. In this study, we present a new oral irinotecan formulation designed as an enteric coated immediate release tablet which in pre-clinical studies has shown good exposure with low variability. METHODS: A phase I, dose escalating study to assess safety, tolerability, pharmacokinetics and efficacy of an oral irinotecan formulation and to establish the maximum tolerated dose (MTD). Each treatment cycle was once-daily irinotecan for 14 days followed by 1 week rest. RESULTS: 25 patients were included across four cohorts; 3 patients were included in cohort 1 (20 mg/m2), 7 patients were included in cohort 2 (30 mg/m2), 3 patients were included in cohort 3 (25 mg/m2) and 12 patients were included in cohort 4 (21 mg/m2). Median age was 67 years, 52% were performance status (PS) 0 while 48% were PS 1. Median number of prior therapies was 3 (range 1-6). MTD was established at 21 mg/m2. No responses were observed. Nine patients (36%) had stable disease (SD), lasting median 19 weeks (range 7-45 weeks). Among these five patients had previously received irinotecan. No grade 3/4 hematologic toxicities were reported. Totally six patients experienced grade 1/2 anemia, three patients had grade 1/2 leucopenia and 1 patient had grade 1 thrombocytopenia. Most common non-hematological grade 1 and 2 adverse events were nausea, fatigue, diarrhea, vomiting and cholinergic syndrome. Grade 3 toxicities included diarrhea, fatigue, nausea and vomiting, no grade 4 events were reported. PK data showed consistent daily exposures during treatment at days 1 and 14 and no drug accumulation. SN-38 interpatient variability was in the same range as after infusion. CONCLUSIONS: Oral irinotecan was generally well tolerated; side effects were manageable and similar in type to those observed with intravenous irinotecan. Hematological toxicities were few and only grade 1/2. In this heavily pre-treated patient population, oral irinotecan demonstrated activity even among patients previously treated with irinotecan. More... »

PAGES

169-178

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-018-3720-7

DOI

http://dx.doi.org/10.1007/s00280-018-3720-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1109785986

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30406838


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00fcmler", 
        "givenName": "I.", 
        "id": "sg:person.01116054207.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116054207.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "S\u00f8rensen", 
        "givenName": "P. Grundtvig", 
        "id": "sg:person.01231302527.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231302527.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palshof", 
        "givenName": "J.", 
        "id": "sg:person.0770606607.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770606607.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "H\u00f8gdall", 
        "givenName": "E.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Skovrider-Ruminski", 
        "givenName": "W.", 
        "id": "sg:person.01115331642.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115331642.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Theile", 
        "givenName": "S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Oncoral Pharma ApS, c/o Jusmedico, Kongevejen 371, Holte, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fullerton", 
        "givenName": "A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Oncoral Pharma ApS, c/o Jusmedico, Kongevejen 371, Holte, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nielsen", 
        "givenName": "P. G.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jensen", 
        "givenName": "B. Vittrup", 
        "id": "sg:person.01015252565.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015252565.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nielsen", 
        "givenName": "D. L.", 
        "id": "sg:person.016446572022.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016446572022.81"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-005-0138-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000431550", 
          "https://doi.org/10.1007/s00280-005-0138-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-005-0138-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000431550", 
          "https://doi.org/10.1007/s00280-005-0138-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejpb.2011.01.021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007131823"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-004-0874-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007848801", 
          "https://doi.org/10.1007/s00280-004-0874-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdl071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008381637"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jconrel.2013.07.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013270357"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.10.047", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019778705"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1011923", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022967950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2013.06.038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023004052"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.tpj.6500072", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023319869", 
          "https://doi.org/10.1038/sj.tpj.6500072"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.tpj.6500072", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023319869", 
          "https://doi.org/10.1038/sj.tpj.6500072"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-05-2368", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024763018"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-010-9528-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026463355", 
          "https://doi.org/10.1007/s10637-010-9528-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jconrel.2010.11.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026546389"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029291056"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-006-0283-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030481794", 
          "https://doi.org/10.1007/s00280-006-0283-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.hoc.2012.03.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031365622"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1026207519884", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040823025", 
          "https://doi.org/10.1023/a:1026207519884"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-198212000-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045278392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-198212000-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045278392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0b013e328330c7d2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047174503"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0b013e328330c7d2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047174503"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0b013e328330c7d2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047174503"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-04-1758", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048263783"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604311", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048648006", 
          "https://doi.org/10.1038/sj.bjc.6604311"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049715252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2011.06.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051799274"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/acs.molpharmaceut.5b00785", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055120185"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.targ-09-c218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063227299"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834009355164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077267"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834009355164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077267"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.2.685", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074265671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a059107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082507231"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1996.14.4.1128", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082892977"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.2.625", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083054557"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.8.2910", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083129507"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083312377", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.15_suppl.e14109", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083945477"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0644-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101397703", 
          "https://doi.org/10.1007/s40262-018-0644-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0644-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101397703", 
          "https://doi.org/10.1007/s40262-018-0644-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0644-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101397703", 
          "https://doi.org/10.1007/s40262-018-0644-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-01", 
    "datePublishedReg": "2019-01-01", 
    "description": "BACKGROUND: Oral drug formulations have several advantages compared to intravenous formulation. Apart from patient convenience and favorable pharmacoeconomics, they offer the possibility of frequent drug administration at home. In this study, we present a new oral irinotecan formulation designed as an enteric coated immediate release tablet which in pre-clinical studies has shown good exposure with low variability.\nMETHODS: A phase I, dose escalating study to assess safety, tolerability, pharmacokinetics and efficacy of an oral irinotecan formulation and to establish the maximum tolerated dose (MTD). Each treatment cycle was once-daily irinotecan for 14\u00a0days followed by 1\u00a0week rest.\nRESULTS: 25 patients were included across four cohorts; 3 patients were included in cohort 1 (20\u00a0mg/m2), 7 patients were included in cohort 2 (30\u00a0mg/m2), 3 patients were included in cohort 3 (25\u00a0mg/m2) and 12 patients were included in cohort 4 (21\u00a0mg/m2). Median age was 67\u00a0years, 52% were performance status (PS) 0 while 48% were PS 1. Median number of prior therapies was 3 (range 1-6). MTD was established at 21\u00a0mg/m2. No responses were observed. Nine patients (36%) had stable disease (SD), lasting median 19 weeks (range 7-45\u00a0weeks). Among these five patients had previously received irinotecan. No grade 3/4 hematologic toxicities were reported. Totally six patients experienced grade 1/2 anemia, three patients had grade 1/2 leucopenia and 1 patient had grade 1 thrombocytopenia. Most common non-hematological grade 1 and 2 adverse events were nausea, fatigue, diarrhea, vomiting and cholinergic syndrome. Grade 3 toxicities included diarrhea, fatigue, nausea and vomiting, no grade 4 events were reported. PK data showed consistent daily exposures during treatment at days 1 and 14 and no drug accumulation. SN-38 interpatient variability was in the same range as after infusion.\nCONCLUSIONS: Oral irinotecan was generally well tolerated; side effects were manageable and similar in type to those observed with intravenous irinotecan. Hematological toxicities were few and only grade 1/2. In this heavily pre-treated patient population, oral irinotecan demonstrated activity even among patients previously treated with irinotecan.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-018-3720-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "83"
      }
    ], 
    "name": "Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics", 
    "pagination": "169-178", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f0a85ac02d7917b40398820983f148f507a8a262f2d4bae53cc757694e1e4b0f"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30406838"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-018-3720-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1109785986"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-018-3720-7", 
      "https://app.dimensions.ai/details/publication/pub.1109785986"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000354_0000000354/records_11724_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00280-018-3720-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-018-3720-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-018-3720-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-018-3720-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-018-3720-7'


 

This table displays all metadata directly associated to this object as RDF triples.

242 TRIPLES      21 PREDICATES      63 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-018-3720-7 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N6956bb8ff105470b8db5064339012f60
4 schema:citation sg:pub.10.1007/s00280-004-0874-2
5 sg:pub.10.1007/s00280-005-0138-9
6 sg:pub.10.1007/s00280-006-0283-9
7 sg:pub.10.1007/s10637-010-9528-x
8 sg:pub.10.1007/s40262-018-0644-7
9 sg:pub.10.1023/a:1026207519884
10 sg:pub.10.1038/sj.bjc.6604311
11 sg:pub.10.1038/sj.tpj.6500072
12 https://app.dimensions.ai/details/publication/pub.1083312377
13 https://doi.org/10.1016/j.ejca.2008.10.026
14 https://doi.org/10.1016/j.ejca.2011.06.002
15 https://doi.org/10.1016/j.ejca.2013.06.038
16 https://doi.org/10.1016/j.ejpb.2011.01.021
17 https://doi.org/10.1016/j.hoc.2012.03.002
18 https://doi.org/10.1016/j.jconrel.2010.11.022
19 https://doi.org/10.1016/j.jconrel.2013.07.022
20 https://doi.org/10.1021/acs.molpharmaceut.5b00785
21 https://doi.org/10.1056/nejmoa1011923
22 https://doi.org/10.1093/annonc/mdl071
23 https://doi.org/10.1093/annonc/mdt002
24 https://doi.org/10.1093/annonc/mdu260
25 https://doi.org/10.1093/oxfordjournals.annonc.a059107
26 https://doi.org/10.1097/00000421-198212000-00014
27 https://doi.org/10.1097/cad.0b013e328330c7d2
28 https://doi.org/10.1158/1078-0432.ccr-04-1758
29 https://doi.org/10.1158/1078-0432.ccr-05-2368
30 https://doi.org/10.1158/1535-7163.targ-09-c218
31 https://doi.org/10.1177/1758834009355164
32 https://doi.org/10.1200/jco.1996.14.4.1128
33 https://doi.org/10.1200/jco.1997.15.2.625
34 https://doi.org/10.1200/jco.1997.15.8.2910
35 https://doi.org/10.1200/jco.1999.17.2.685
36 https://doi.org/10.1200/jco.2004.10.047
37 https://doi.org/10.1200/jco.2010.28.15_suppl.e14109
38 schema:datePublished 2019-01
39 schema:datePublishedReg 2019-01-01
40 schema:description BACKGROUND: Oral drug formulations have several advantages compared to intravenous formulation. Apart from patient convenience and favorable pharmacoeconomics, they offer the possibility of frequent drug administration at home. In this study, we present a new oral irinotecan formulation designed as an enteric coated immediate release tablet which in pre-clinical studies has shown good exposure with low variability. METHODS: A phase I, dose escalating study to assess safety, tolerability, pharmacokinetics and efficacy of an oral irinotecan formulation and to establish the maximum tolerated dose (MTD). Each treatment cycle was once-daily irinotecan for 14 days followed by 1 week rest. RESULTS: 25 patients were included across four cohorts; 3 patients were included in cohort 1 (20 mg/m2), 7 patients were included in cohort 2 (30 mg/m2), 3 patients were included in cohort 3 (25 mg/m2) and 12 patients were included in cohort 4 (21 mg/m2). Median age was 67 years, 52% were performance status (PS) 0 while 48% were PS 1. Median number of prior therapies was 3 (range 1-6). MTD was established at 21 mg/m2. No responses were observed. Nine patients (36%) had stable disease (SD), lasting median 19 weeks (range 7-45 weeks). Among these five patients had previously received irinotecan. No grade 3/4 hematologic toxicities were reported. Totally six patients experienced grade 1/2 anemia, three patients had grade 1/2 leucopenia and 1 patient had grade 1 thrombocytopenia. Most common non-hematological grade 1 and 2 adverse events were nausea, fatigue, diarrhea, vomiting and cholinergic syndrome. Grade 3 toxicities included diarrhea, fatigue, nausea and vomiting, no grade 4 events were reported. PK data showed consistent daily exposures during treatment at days 1 and 14 and no drug accumulation. SN-38 interpatient variability was in the same range as after infusion. CONCLUSIONS: Oral irinotecan was generally well tolerated; side effects were manageable and similar in type to those observed with intravenous irinotecan. Hematological toxicities were few and only grade 1/2. In this heavily pre-treated patient population, oral irinotecan demonstrated activity even among patients previously treated with irinotecan.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree false
44 schema:isPartOf N3e1c16ae7ee747b9aea3e81c51d00fb0
45 N57a47009b02e4d7db3e9f866fbd3b771
46 sg:journal.1088364
47 schema:name Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
48 schema:pagination 169-178
49 schema:productId N03e5a67b699d4028acabbe45b39b3582
50 N31033102cd7d4886b29be9cf0c1d3cee
51 N4df19aafc3e34e08887266e2966ebaf7
52 Na3bdee7dbcb04a0f8056a6fe3739a949
53 Nc2371b275c3444549e9a0361c8bde768
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109785986
55 https://doi.org/10.1007/s00280-018-3720-7
56 schema:sdDatePublished 2019-04-11T11:21
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher N0c4b38ed8ee0421cb2326f51ec5ab8e8
59 schema:url https://link.springer.com/10.1007%2Fs00280-018-3720-7
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N03e5a67b699d4028acabbe45b39b3582 schema:name dimensions_id
64 schema:value pub.1109785986
65 rdf:type schema:PropertyValue
66 N06f229e3a4764ff1ab2947aefe0edcf1 rdf:first N3e557fbc77cd42f0aa666f16bb7abaa1
67 rdf:rest N4840f7aca57f4ae58464e6482c376836
68 N09beed66e5404b3ea7d0adb3c419869c schema:name Oncoral Pharma ApS, c/o Jusmedico, Kongevejen 371, Holte, Denmark
69 rdf:type schema:Organization
70 N0c4b38ed8ee0421cb2326f51ec5ab8e8 schema:name Springer Nature - SN SciGraph project
71 rdf:type schema:Organization
72 N168a3ca7f7964ba792d71e88b62915bd rdf:first sg:person.016446572022.81
73 rdf:rest rdf:nil
74 N2d926af41013424c92a82a9331e1770d rdf:first Nd1cd138502194aea8fedac85440d4aec
75 rdf:rest N5a5fadf1d43145afaec4a0c72ed4eb74
76 N31033102cd7d4886b29be9cf0c1d3cee schema:name doi
77 schema:value 10.1007/s00280-018-3720-7
78 rdf:type schema:PropertyValue
79 N3e1c16ae7ee747b9aea3e81c51d00fb0 schema:issueNumber 1
80 rdf:type schema:PublicationIssue
81 N3e557fbc77cd42f0aa666f16bb7abaa1 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
82 schema:familyName Høgdall
83 schema:givenName E.
84 rdf:type schema:Person
85 N4840f7aca57f4ae58464e6482c376836 rdf:first sg:person.01115331642.10
86 rdf:rest Nd9124f0411c747118ced13c93077707d
87 N4df19aafc3e34e08887266e2966ebaf7 schema:name nlm_unique_id
88 schema:value 7806519
89 rdf:type schema:PropertyValue
90 N55c21b4207bf4d798c1bcd2d437e44a8 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
91 schema:familyName Theile
92 schema:givenName S.
93 rdf:type schema:Person
94 N57a47009b02e4d7db3e9f866fbd3b771 schema:volumeNumber 83
95 rdf:type schema:PublicationVolume
96 N5a5fadf1d43145afaec4a0c72ed4eb74 rdf:first sg:person.01015252565.45
97 rdf:rest N168a3ca7f7964ba792d71e88b62915bd
98 N6956bb8ff105470b8db5064339012f60 rdf:first sg:person.01116054207.20
99 rdf:rest N8a2ad617e6bf411a9e8f88a2e4fe9449
100 N74984e1d05654515b3254953988457d3 schema:name Oncoral Pharma ApS, c/o Jusmedico, Kongevejen 371, Holte, Denmark
101 rdf:type schema:Organization
102 N8a2ad617e6bf411a9e8f88a2e4fe9449 rdf:first sg:person.01231302527.69
103 rdf:rest Nb4581b83a1f040d48274d56ef398f647
104 N8bd3b2abc2f149528c3c6a735423eb23 rdf:first Na4e219e91ecd4e919ede6213f030ee23
105 rdf:rest N2d926af41013424c92a82a9331e1770d
106 Na3bdee7dbcb04a0f8056a6fe3739a949 schema:name pubmed_id
107 schema:value 30406838
108 rdf:type schema:PropertyValue
109 Na4e219e91ecd4e919ede6213f030ee23 schema:affiliation N74984e1d05654515b3254953988457d3
110 schema:familyName Fullerton
111 schema:givenName A.
112 rdf:type schema:Person
113 Nb4581b83a1f040d48274d56ef398f647 rdf:first sg:person.0770606607.23
114 rdf:rest N06f229e3a4764ff1ab2947aefe0edcf1
115 Nc2371b275c3444549e9a0361c8bde768 schema:name readcube_id
116 schema:value f0a85ac02d7917b40398820983f148f507a8a262f2d4bae53cc757694e1e4b0f
117 rdf:type schema:PropertyValue
118 Nd1cd138502194aea8fedac85440d4aec schema:affiliation N09beed66e5404b3ea7d0adb3c419869c
119 schema:familyName Nielsen
120 schema:givenName P. G.
121 rdf:type schema:Person
122 Nd9124f0411c747118ced13c93077707d rdf:first N55c21b4207bf4d798c1bcd2d437e44a8
123 rdf:rest N8bd3b2abc2f149528c3c6a735423eb23
124 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
125 schema:name Medical and Health Sciences
126 rdf:type schema:DefinedTerm
127 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
128 schema:name Public Health and Health Services
129 rdf:type schema:DefinedTerm
130 sg:journal.1088364 schema:issn 0344-5704
131 1432-0843
132 schema:name Cancer Chemotherapy and Pharmacology
133 rdf:type schema:Periodical
134 sg:person.01015252565.45 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
135 schema:familyName Jensen
136 schema:givenName B. Vittrup
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015252565.45
138 rdf:type schema:Person
139 sg:person.01115331642.10 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
140 schema:familyName Skovrider-Ruminski
141 schema:givenName W.
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115331642.10
143 rdf:type schema:Person
144 sg:person.01116054207.20 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
145 schema:familyName Kümler
146 schema:givenName I.
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116054207.20
148 rdf:type schema:Person
149 sg:person.01231302527.69 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
150 schema:familyName Sørensen
151 schema:givenName P. Grundtvig
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231302527.69
153 rdf:type schema:Person
154 sg:person.016446572022.81 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
155 schema:familyName Nielsen
156 schema:givenName D. L.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016446572022.81
158 rdf:type schema:Person
159 sg:person.0770606607.23 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
160 schema:familyName Palshof
161 schema:givenName J.
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770606607.23
163 rdf:type schema:Person
164 sg:pub.10.1007/s00280-004-0874-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007848801
165 https://doi.org/10.1007/s00280-004-0874-2
166 rdf:type schema:CreativeWork
167 sg:pub.10.1007/s00280-005-0138-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000431550
168 https://doi.org/10.1007/s00280-005-0138-9
169 rdf:type schema:CreativeWork
170 sg:pub.10.1007/s00280-006-0283-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030481794
171 https://doi.org/10.1007/s00280-006-0283-9
172 rdf:type schema:CreativeWork
173 sg:pub.10.1007/s10637-010-9528-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1026463355
174 https://doi.org/10.1007/s10637-010-9528-x
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/s40262-018-0644-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101397703
177 https://doi.org/10.1007/s40262-018-0644-7
178 rdf:type schema:CreativeWork
179 sg:pub.10.1023/a:1026207519884 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040823025
180 https://doi.org/10.1023/a:1026207519884
181 rdf:type schema:CreativeWork
182 sg:pub.10.1038/sj.bjc.6604311 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048648006
183 https://doi.org/10.1038/sj.bjc.6604311
184 rdf:type schema:CreativeWork
185 sg:pub.10.1038/sj.tpj.6500072 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023319869
186 https://doi.org/10.1038/sj.tpj.6500072
187 rdf:type schema:CreativeWork
188 https://app.dimensions.ai/details/publication/pub.1083312377 schema:CreativeWork
189 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/j.ejca.2011.06.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051799274
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/j.ejca.2013.06.038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023004052
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/j.ejpb.2011.01.021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007131823
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1016/j.hoc.2012.03.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031365622
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1016/j.jconrel.2010.11.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026546389
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1016/j.jconrel.2013.07.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013270357
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1021/acs.molpharmaceut.5b00785 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055120185
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1056/nejmoa1011923 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022967950
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1093/annonc/mdl071 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008381637
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1093/annonc/mdt002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049715252
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1093/annonc/mdu260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029291056
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1093/oxfordjournals.annonc.a059107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082507231
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1097/00000421-198212000-00014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045278392
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1097/cad.0b013e328330c7d2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047174503
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1158/1078-0432.ccr-04-1758 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048263783
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1158/1078-0432.ccr-05-2368 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024763018
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1158/1535-7163.targ-09-c218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063227299
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1177/1758834009355164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064077267
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1200/jco.1996.14.4.1128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082892977
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1200/jco.1997.15.2.625 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083054557
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1200/jco.1997.15.8.2910 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083129507
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1200/jco.1999.17.2.685 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074265671
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1200/jco.2004.10.047 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019778705
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1200/jco.2010.28.15_suppl.e14109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083945477
238 rdf:type schema:CreativeWork
239 https://www.grid.ac/institutes/grid.411646.0 schema:alternateName Gentofte Hospital
240 schema:name Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark
241 Department of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark
242 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...